PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-10-20
DOI
10.3389/fimmu.2022.1049043
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The “digital biopsy” in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT
- (2022) Lavinia Monaco et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
- (2022) Kevin Park et al. Frontiers in Cell and Developmental Biology
- Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
- (2022) Tae Kon Kim et al. NATURE REVIEWS DRUG DISCOVERY
- Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens
- (2021) Long Zhao et al. BRITISH JOURNAL OF RADIOLOGY
- A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
- (2021) Gil Awada et al. Cancers
- Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
- (2021) Agnese Paderi et al. Cancers
- Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
- (2021) Donghui Wang et al. Frontiers in Oncology
- The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression
- (2021) Karolien Vekens et al. Clinical Lung Cancer
- Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[18F]FDG PET/CT
- (2021) Caixia Wu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
- (2021) Yong Fan et al. Frontiers in Oncology
- Correlation Between Dual-Time-Point FDG PET and Tumor Microenvironment Immune Types in Non-Small Cell Lung Cancer
- (2021) Jianyuan Zhou et al. Frontiers in Oncology
- Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study
- (2021) Kenji Morimoto et al. Frontiers in Oncology
- Diagnostic test accuracy of 18F-FDG PET/CT for prediction of programmed death ligand 1 (PD-L1) expression in solid tumours: a meta-analysis
- (2021) H.Y. Seol et al. CLINICAL RADIOLOGY
- Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab
- (2021) Filippo G. Dall’Olio et al. EUROPEAN JOURNAL OF CANCER
- Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST
- (2021) Kazuhiro Kitajima et al. Japanese Journal of Radiology
- First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer
- (2021) Anna-Larissa Nadia Niemeijer et al. JOURNAL OF NUCLEAR MEDICINE
- Relationship of the standard uptake value of 18F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm
- (2021) Soeun Park et al. Scientific Reports
- Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
- (2021) Wei Mu et al. Journal for ImmunoTherapy of Cancer
- The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
- (2021) Matteo Bauckneht et al. Cancers
- FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
- (2021) F. Dimitriou et al. ANNALS OF ONCOLOGY
- 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer
- (2021) I.C. Kok et al. ANNALS OF ONCOLOGY
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- (2021) Golnaz Morad et al. CELL
- Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study
- (2021) Nežka Hribernik et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Tumour burden and efficacy of immune-checkpoint inhibitors
- (2021) Filippo G. Dall’Olio et al. Nature Reviews Clinical Oncology
- Prognostic importance of SUV-max values evaluated by 18F-FDG-PET/CT before nivolumab treatment in patients with metastatic renal cell carcinoma
- (2021) Ilkay GULTURK et al. QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer
- (2021) Jianyuan Zhou et al. Frontiers in Oncology
- Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by 18F-FDG PET/CT Radiomics and Clinicopathological Characteristics
- (2021) Jihui Li et al. Frontiers in Oncology
- FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer
- (2020) Tomoko Hirakata et al. BREAST CANCER RESEARCH AND TREATMENT
- Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma
- (2020) Maria Togo et al. BRITISH JOURNAL OF CANCER
- 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer
- (2020) Kyle G. Mitchell et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- ICOS Is an Indicator of T-cell–Mediated Response to Cancer Immunotherapy
- (2020) Zunyu Xiao et al. CANCER RESEARCH
- Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4
- (2020) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The immunological Warburg effect: Can a metabolic‐tumor‐stroma score (MeTS) guide cancer immunotherapy?
- (2020) Peter J. Siska et al. IMMUNOLOGICAL REVIEWS
- Imaging the cancer immune environment and its response to pharmacological intervention- Part 1- The role of FDG PET/CT
- (2020) Amir Iravani et al. JOURNAL OF NUCLEAR MEDICINE
- 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
- (2020) Annie Wong et al. CANCER IMAGING
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
- (2020) Eli P. Darnell et al. Current Oncology Reports
- PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
- (2020) Xiaodong Wu et al. EJNMMI Research
- Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
- (2020) Kosuke Hashimoto et al. Journal of Clinical Medicine
- 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
- (2020) Giulia Polverari et al. Cancers
- The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
- (2020) Yuanyuan Zhang et al. Cellular & Molecular Immunology
- Association between the occurrence and spectrum of immune-related adverse events and efficacy of pembrolizumab in Asian patients with advanced urothelial cancer: Multicenter retrospective analyses and systematic literature review
- (2020) Toshiki Kijima et al. Clinical Genitourinary Cancer
- Relationship between SP142 PD-L1 Expression and 18F-FDG Uptake in Non-Small-Cell Lung Cancer
- (2020) Long Zhao et al. Contrast Media & Molecular Imaging
- Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study
- (2020) David Chardin et al. Journal for ImmunoTherapy of Cancer
- Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1
- (2020) Angelo Castello et al. Frontiers in Oncology
- FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer
- (2020) Romain-David Seban et al. ANNALS OF NUCLEAR MEDICINE
- Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET
- (2020) Federico Simonetta et al. CLINICAL CANCER RESEARCH
- Imaging findings of immune checkpoint inhibitor associated pancreatitis
- (2020) Jeeban P. Das et al. EUROPEAN JOURNAL OF RADIOLOGY
- Imaging the cancer immune environment and its response to pharmacological intervention- Part 2- The Role of Novel PET Agents
- (2020) Amir Iravani et al. JOURNAL OF NUCLEAR MEDICINE
- Non-invasive decision support for NSCLC treatment using PET/CT radiomics
- (2020) Wei Mu et al. Nature Communications
- Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
- (2020) Ou Yamaguchi et al. Scientific Reports
- The potential of 18F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer
- (2020) Lihua Wang et al. LUNG CANCER
- Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer
- (2019) Ruohua Chen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
- (2019) Lucas Goldfarb et al. EJNMMI Research
- Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
- (2019) Tomomi Nobashi et al. CLINICAL NUCLEAR MEDICINE
- Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non–Small Cell Lung Cancer
- (2019) Lucian Beer et al. CLINICAL NUCLEAR MEDICINE
- The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer
- (2019) Shinsuke Sasada et al. BREAST CANCER RESEARCH AND TREATMENT
- 18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer
- (2019) Mario Jreige et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
- (2019) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response
- (2019) Joseph Vento et al. Journal for ImmunoTherapy of Cancer
- New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer
- (2019) Yang Wang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Immunity, Hypoxia and Metabolism - the ménage à trois of cancer: implications for immunotherapy
- (2019) Carla Riera-Domingo et al. PHYSIOLOGICAL REVIEWS
- Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
- (2019) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting
- (2019) Neeta Pandit-Taskar et al. JOURNAL OF NUCLEAR MEDICINE
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy
- (2019) Wei Mu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Hyper-progressive Disease in Patients With Non–Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of 18F-FDG PET/CT
- (2019) Angelo Castello et al. JOURNAL OF NUCLEAR MEDICINE
- Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
- (2018) Tina Cascone et al. Cell Metabolism
- The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma
- (2018) Christos Sachpekidis et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
- (2018) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas
- (2018) Tsuyoshi Hamada et al. OncoImmunology
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
- (2018) Jason Zhu et al. Journal for ImmunoTherapy of Cancer
- Interferon-gamma PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy
- (2018) Heather M Gibson et al. CANCER RESEARCH
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Adverse effects and radiological manifestations of new immunotherapy agents
- (2018) Yen Zhi Tang et al. BRITISH JOURNAL OF RADIOLOGY
- Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy
- (2018) Kimiteru Ito et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect
- (2018) Yang Du et al. EUROPEAN RADIOLOGY
- F-18 FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma
- (2018) Kimiteru Ito et al. JOURNAL OF NUCLEAR MEDICINE
- 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab
- (2018) Christos Sachpekidis et al. MELANOMA RESEARCH
- 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
- (2018) Frederike Bensch et al. NATURE MEDICINE
- PD-1 Blockade–induced Inflammatory Arthritis
- (2018) Tomomi Nobashi et al. RADIOLOGY
- Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
- (2017) Hoda Anwar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Oxygen availability and metabolic reprogramming in cancer
- (2017) Hong Xie et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
- (2017) Mohammad Rashidian et al. JOURNAL OF EXPERIMENTAL MEDICINE
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
- (2017) Robert Brody et al. LUNG CANCER
- ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer
- (2017) Emily B. Ehlerding et al. MOLECULAR PHARMACEUTICS
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses
- (2017) Seungho Lee et al. Journal of Gastric Cancer
- Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery
- (2016) Egesta Lopci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
- (2011) Stephanos Pavlides et al. CELL CYCLE
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search